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Summary 
The natural killer (NK) cell-specific p58 molecules EB6 and GL183 have been shown to represent 
the putative surface receptors for two distinct groups of human histocompatibility leukocyte 
antigen (HLA) C alleles. Interaction between p58 receptors  and class I molecules expressed on 
target cells results in inhibition of the NK-mediated cytolytic activity and thus in target cell 
protection. In the present study, we show that EB6 molecules may also act as receptors mediating 
NK cell triggering. Activatory EB6 molecules were fouiad to be confined only to certain donors. 
Moreover,  in these donors, only a fraction of EB6 + NK clones expressed the activatory form 
of EB6 molecules, while the remaining clones expressed the conventional inhibitory form. Bio- 
chemical analysis of the activatory EB6 molecules revealed a molecular mass of "~50 kD (pS0), 
thus differing from the 58-kD inhibitory form. This difference was not due to differential glycosy- 
lation of the same protein, as revealed by deglycosylation experiments on isolated EB6 molecules. 
Treatment of purified p58 or pS0/EB6 molecules with proteolytic enzymes, including V8-protease, 
chymotrypsin, and papain, showed only minor differences in the resulting peptides. Treatment 
with pepsin followed by two-dimensional peptide mapping demonstrated that, although the 
majority of peptides migrated in identical positions, differences between the two forms could 
be detected for at least one major peptide. Anti-EB6 monoclonal antibody (mAb)-mediated cross- 
linking of p50 molecules was required to trigger the cytolytic activity and the intracellular cal- 
cium ([Ca++]i)  increases in appropriate NK clones.  Likewise, mAb-mediated cross-linking of 
the p58 EB6 molecules was needed to inhibit the cytolytic activity; however, in this case, no 
[Ca +  +  ]i increases could be detected. In NK clones expressing the inhibitory p58 EB6 receptors, 
soluble anti-EB6 mAb prevented recognition of protective Cw4 molecules and reconstituted target 
cell lysis. In contrast, in clones expressing the activatory p50/EB6 receptor,  EB6 masking fre- 
quently resulted in partial inhibition of the cytolytic activity against Cw4 + target cells. There- 
fore, it appears that NK clones  expressing the p50/EB6 receptors  are induced to lyse Cw4 + 
target cells upon specific interaction with Cw4 molecules.  This concept was further substan- 
tiated by experiments in which target cells were represented by the HLA-negative LCL721.221 
cell line transfected with the Cw4 allele. Phenotypic and functional analysis of a large number 
of NK clones showed that clones expressing the activatory p50/EB6 molecules consistently coex- 
pressed inhibitory receptors for other HLA class I alleles. Taken together, our data indicate that 
recognition of dass I molecules may result either in inhibition or in activation of NK-mediated 
cytolysis. However, the inhibitory pathway appears to dominate the activatory one, thus preventing 
lysis of class I-protected autologous normal cells. 
ecent data in mouse and in humans have provided direct 
evidence that NK cells recognize MHC class I mole- 
cules on target cells (1-7).  This recognition results in the 
generation of a negative signal  that inhibits the NK cell- 
mediated cytolytic activity, thus preventing lysis of target cells 
(8). Clonal analysis  of human NK cells has allowed the demon- 
stration of a higher degree of complexity in HLA class I rec- 
ognition (9, 10). Indeed, groups of NK clones were shown 
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than any HLA class I molecule. These studies provided dear 
evidence for the existence of clonal heterogeneity among NK 
ceUs regarding their ability to recognize different HLA class 
I alleles. Specific recognition of class I alldes is mediated by 
surface receptors characterized by a donal distribution.  In 
humans,  the first identified receptors are represented by the 
p58 molecules GL183 (11) and EB6 (12),  which have been 
shown to mediate specific recognition of different groups of 
HLA-C alleles (13). More recently, distinct receptors specific 
for different groups of HLA-B alleles have been identified with 
the CD94 (14) and the NKB1 (15) surface molecules. All of 
these receptors have been shown to inhibit the cytolytic ac- 
tivity of NK cells upon interaction with their HLA class I 
ligands.  In addition, a similar inhibitory effect occurred by 
inducing cross-linking of the receptors with specific mAbs 
in a redirected killing assay (13, 14). In the absence of cross- 
linking, (soluble) antireceptor mAbs were shown to prevent 
recognition of HLA class I alleles, thus resulting in lysis of 
class I "protected" target cells (13-15). Taken together, these 
data led to the concept that  the expression of MHC dass 
I molecules prevents target cell lysis by interacting with specific 
inhibitory receptors expressed on NK cells. In accordance with 
the "missing self" hypothesis (1-5),  the loss (or masking) 
of given HLA class I  alleles  (e.g.,  in some viral infections 
or tumors) results in the lack of interaction with the inhibi- 
tory NK receptor and thus in target cell lysis. 
In the present report,  we provide evidence that  the NK 
receptors for HLA class I may function not only as inhibi- 
tory receptors. We show that the EB6 molecule, specific for 
a group of HLA-C alleles, may also function as an activatory 
receptor.  The activatory EB6 receptor displays  a molecular 
mass of ~50 kD, thus differing from the 58-kD inhibitory 
receptor.  The expression of activatory receptors appears always 
to be balanced by the coexpression of one or more inhibitory 
receptors. 
Materials  and Methods 
Antibodies.  mAbJT3A (IgG2a anti-CD3), HP2.6 (IgG2a anti- 
CD4), B9.4 (IgG2b anti-CD8), GL183 (IgG1 anti-p58), ),249 (IgM 
anti-p58), EB6 (IgG1 anti-p58), XA-141 (IgM anti-p58), XA-185 
(IgG1 anti-CD94), XA88 (IgG3 anti-CD94), Y9 (IgM anti-CD94), 
KD1 (IgG2a anti-CD16),  K218 (IgG1 anti-CD56),  A6-220 (IgM 
anti-CD56),  6A4 (IgG1 anti-HLA class I), and A6-136 (IgM anti- 
HLA class I) (14) were used in this study. F(ab')2 fragments  of 
the relevant mAbs were derived as previously described (13). 
Detection of Cytolytic Activity Mediated by NK Clones.  NK clones 
were obtained by limiting dilution, as previously described (11, 16). 
The cytolytic activity of cloned NK cells was assessed in a 4-h SlCr 
release assay  in which effector cells were tested against the following 
target cells: the murine  P815 cell line, the human  CIR cell line 
(13, 14), and the human  HLA class I-negative  LCL721.221 cell 
line (17), either  untransfected  or transfected with Cw3 or Cw4 
alleles (kindly provided by Dr. Roberto Biassoni, Istituto Nazionale 
per h  Kicerca sul Cancro and Centro di Biotecnologie Avanzate, 
Genoa, Italy). 
These target cells were used at 5 x  103/well, and the final E/T 
ratio is indicated in the text. The percentage of specific lysis was 
determined as previously described (16). mAbs were added at the 
onset of the cytolytic assay before adding target cells. The mAb 
concentrations used in the various assays are indicated in the text. 
Flow Cytofluorimetric  Analysis,  Cells  were stained with the appro- 
priate mAb followed by fluoresceinated goat anti-mouse (GAM) 1 
Ig (Southern Biotechnology Associated, Birmingham,  AL). Con- 
trol aliquots were stained with the fluoresceinated reagent alone. 
All samples were then analyzed on a flow cytometer (FACStar  | 
Becton Dickinson & Co., Mountain  View, CA) gated to exclude 
nonviable cells (11). 
Determination  of Intracellulor Free Calcium  ([Ca++]i) Increases. 
Determination  of [Ca++]i was performed as previously described 
(18). Briefly, CD3-CD16 + clonal cell populations (2.5  x  lOS/m1) 
were loaded with the acetoxymethyl ester of Fura-2 (1 #M final 
concentration; Sigma Chemical Co., Cockeysville, MD) in the cal- 
cium assay buffer (17). The fluorescence of the cellular suspension 
was monitored with a spectrofluorimeter (LS-5; Perkin-Elmer Corp., 
Norwalk, CT) using a 2-ml quartz  cuvette. The cell suspension 
was excited at 345-348  nm, and fluorescence emission was mea- 
sured at 496-510 nm. All measurements were performed at 37~ 
using a thermostatically controlled cuvette holder and stirring ap- 
paratus. [Ca ++ ]i was calculated by the method of Grynkiewicz et 
al. (19). Triggering of NK cells was achieved by adding into the 
cuvette 5 #g/m1 of anti-CD16  mAb KD1 (the optimal  amount 
of CD16 mAb was determined in each experiment starting  from 
20 to 0.1 #g/ml). EB6- or XA185-mediated [Ca++]i increases were 
evaluated in Fura-2-1oaded CD3-CD16 + NK ceils upon addition 
of 20 #g/ml (&terminated  in preliminary experiments) polyclonal 
anti-IgG1 GAM (Southern Biotechnology Associated) after treat- 
ment of the ceils with 5 #g/ml of EB6 or XA185 mAbs at 0~ 
for 30-45 min. 
Biochemical Characterization of the EB6 Molecules.  Sepharose  cy- 
anogen bromide (Pharmacia Biotech Inc., Hscataway, NJ)-coupled 
anti-EB6 mAb was used to immunoprecipitate EB6 molecules from 
1% NP-40 lysates of NK populations or NK clones surface labeled 
with mI (DuPont-New England  Nuclear, Wilmington,  DE) as 
previously described (12). Immunoprecipitates were analyzed in dis- 
continuous  SDS-PAGE and  subjected to autoradiography  using 
Hyperfilm-MP  (Amersham International,  Little Chalfont,  UK). 
Where indicated, bands were cut from dried gel and proteins were 
eluted using the centrilutor  (Amicon, Beverly, MA). The eluted 
proteins were precipitated in 20% TCA at 4~  for 2 h, washed 
four times with cold (- 20~  acetone, and dried in a vacuum cen- 
trifugal  concentrator  (Jouan, Saint Herblain,  France). 
Deglycosylation of EB6 Molecules.  For N-glycanase (Genzyme 
Corp.,  Cambridge,  MA) digestion,  EB6 immunoprecipitates  or 
EB6-eluted proteins were resuspended in 30 #1 of digestion buffer 
(0.4 M Tris, pH 8, 1% NP-40, 0.1% SDS, 10 mM 2-ME) and boiled 
(filtered if immunoprecipitates were used), and 0.125 U of recom- 
binant N-glycanase was added to each sample. Digestion was per- 
formed at 37~  for 22 h. For neuraminidase (Sigma Chemical Co.) 
and O-glycanase (Genzyme Corp.) digestion, immunoprecipitates 
were resuspended in 50 #1 of digestion buffer (15 mM sodium phos- 
phate, pH 7, 10 mM calcium acetate, 1% NP-40, 0.1%  SDS, 10 
mM 2-ME), boiled, and filtered; 0.05 U of neuraminidase was added 
for 1 h at 37~  followed by 2 mU of O-glycanase for 20 h at 37~ 
After digestions, samples were diluted with SDS sample buffer 
and analyzed by SDS-PAGE. Control (undigested) samples were 
subjected to the same conditions without adding of enzymes (12). 
Peptide Mapping.  One-dimensional peptide mapping ofEB6 mol- 
t Abbreviations  used in thispaper: [Ca++]i, intracellular calcium; GAM, goat 
anti-mouse. 
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adding 500 ng of endoproteinase GIu-C (V8-protease), papain, or 
chymotrypsin (Sigma Chemical Co.) to each well.  Control (un- 
digested) samples were subjected to the same conditions without 
adding of enzymes. Two-dimensional peptide-mapping analysis was 
performed as previously described (12) using Multiphor II (Phar- 
macia Biotech Inc.) for the first dimension. 
Results 
Positive versus Negative Regulation of the Cytolytic Activity 
Mediated by EB6 Molecules in Different NK Clones.  Clones 
expressing  the  GL183-/EB6 +  phenotype were  shown  to 
spedfically recognize HLA-Cw4 and related alleles (13, 21). 
The interaction between EB6 (p58) receptors and HLA-Cw4 
molecules results in an inhibitory signal that suppresses the 
cytolytic activity of these clones. Moreover, in redirected killing 
assays, cross-linking of EB6 molecules induced by specific 
mAbs (of IgG but not of IgM isotype) strongly inhibited 
the cytolytic activity of GL183-/EB6 + clones against the 
FcyK + P815 target cells, thus mimicking the effect of the 
EBr-mediated recognition of Cw4 molecules (13). Such func- 
tional  behavior  of GL183-/EB6 +  clones  occurs  in  most 
donors analyzed (12).  However, in some donors, unexpect- 
edly, a fraction of GL183-/EB6 + clones was found to kill 
target cells expressing Cw4 molecules. Fig. 1 shows GL183- / 
EB6 +  clones isolated  from  two  representative  donors.  In 
donor E.C.  (Fig.  1 A),  all clones failed to lyse the Cw4- 
protected C1R cells (13,  14), whereas, in the case of donor 
R.P. (Fig. 1 B), a large proportion of clones efIidently killed 
the same target cells. To analyze whether this unusual func- 
tional behavior reflected the inability of EB6 molecules to 
mediate inhibitory  signals,  GL183-/EB6 +  clones isolated 
from donor R.P. or E.C. were analyzed in a redirected killing 
assay against P815 cells in the presence or in the absence of 
anti-EB6 mAb (IgG1). As shown in Fig. 2, while the cyto- 
lytic activity of all NK clones derived from donor E.C. was 
strongly inhibited in the presence of anti-EB6 mAb (12), an 
opposite effect was detected in the majority of clones derived 
from donor R.P. Moreover, enhancement of P815 target cell 
lysis occurred only in those clones that lysed (Cw4 +) C1R 
target cells, whereas inhibition of lysis consistently paralleled 
the inability of clones to lyse C1R cells. 
Although not shown, both the inhibitory and the activa- 
tory effects were detectable at similar mAb concentrations. 
In addition, no opposite functional effects could be elicited 
in a given clone by different mAb concentrations. 
We next analyzed whether the EB6-mediated triggering 
ofcytolytic activity was consequent to mAb-mediated cross- 
linking of EB6 molecules. Cross-linking of p58 molecules 
was previously shown to be required for inducing an inhibi- 
tory effect (13).  To this end, we evaluated the effect of the 
F(ab')2  fragments  of anti-EB6  mAbs  under  the  same ex- 
perimental conditions. In these experiments, the F(ab')2 frag- 
ment did not modify the magnitude of the cytolytic activity, 
thus indicating that cross-linking of EB6 molecules is required 
also  to  induce activatory  signals  via  EB6  molecules (not 
shown). 
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Figure 1.  Cytolytic activity of GL183-/EB6+ clones against Cw4+ 
target cells. In this experiment,  18 NK clones derived from donor E.C. 
(A) were compared with 18 NK clones derived from donor R..P. (B) for 
their cytolytic activity against C1R (Cw4 *) target calls. 15 clones from 
each donor were GL183-/EB6 + (closed circles), and 3 clones expressing 
the GL183-/EB6- phenotype (open triangles) are shown for comparison. 
Data are expressed as the percentage of specific slCr rdease at an E/T ratio 
of 5:1. Each symbol corresponds to the cytolytic activity of individual clones. 
[Ca +  +~ Increments Induced by Anti-EB6 raAbs in Clones Ex- 
pressing Activatory versus Inhibitory EB6 Receptors.  In view of 
the opposite effects on cytolysis mediated by EB6 molecules 
in different NK clones, we analyzed whether differences could 
also be detected in an early event of signal transduction, such 
as the [Ca + +]i mobilization in response to mAb-mediated 
cross-linking of the receptors. As shown in Fig. 3, a repre- 
sentative done, characterized by an inhibitory EB6 receptor, 
did not display [Ca + +]i  increments after stimulation with 
anti-EB6 mAb.  Notably,  [Ca*+]i  increments could be in- 
duced in the same done after stimulation with anti-CD16 
mAbs. On the contrary, in clones equipped with an activa- 
tory EB6 receptor,  strong [Ca*+]i  increments in response 
to anti-EB6  mAbs were detected. Similar results were ob- 
tained in all NK clones analyzed (i.e.,  19 clones expressing 
an inhibitory EB6 receptor and 8 clones equipped with an 
activatory receptor). These clones were derived not only from 
donor E.C.  or R.P.  but also from four additional donors. 
Activatory and Inhibitory EB6 Receptors Display Different Mo- 
lecular Masses.  In these experiments, we analyzed the sur- 
face molecules immunoprecipitated by anti-EB6 mAb from 
12SI-sufface-labded NK clones that expressed either inhibi- 
tory or activatory EB6 molecules. The clones analyzed were 
derived from donor E.C. or R.P.; from both donors we also 
derived polyclonal NK cell populations, which, after removal 
of GL183 + cells,  displayed a homogeneous GL183-/EB6 + 
phenotype. As shown in Fig. 4, a striking correlation existed 
between the type of functional response dicited via EB6 mol- 
ecules (i.e., inhibition or activation) and their molecular mass 
as analyzed by SDS-PAGE. Thus, in clones from donor E.C. 
(consistently characterized by the expression of inhibitory EB6 
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Figure  2.  Anti-EB6 mAb can 
inhibit or activate the cytolytic ac- 
tivity  of  GL183-/EB6*  NK 
clones  against  P815 target  cells. 
The cytolytic activity of 10 NK 
clones  derived from donor E.C. 
and 10 NK clones derived from 
donor R.P. was analyzed in a re- 
directed killing assay either in the 
presence (closed bars) or in the ab- 
sence (open bars) of anti-EB6 mAb 
(IgG1).  Data are expressed as the 
percentage of specific SICr release 
at an E/T ratio of 5:1. 
receptors) (12),  the molecular mass of the immunoprecipi- 
tated EB6 molecules was ~58 kD (not shown), thus corre- 
sponding to the previously described p58 molecules (12). In 
contrast, EB6 molecules immunoprecipitated from clones iso- 
lated from donor R.P.  and further  selected on the basis of 
the expression of activatory EB6 receptors had an apparent 
molecular  mass of "~50 kD (Fig.  4, lanes G  and H).  It is 
of note that the EB6 mol~ules immunoprecipitated from poly- 
clonal GL183-/EB6 + NK population derived from donor 
R.P. displayed two distinct bands of 58 and 50 kD, respec- 
tively (Fig.  4, lanes B and E). In contrast,  only the 58-kD 
band  could  be  immunoprecipitated  from  the  polyclonal 
GL183-/EB6 § NK cell population derived from donor E.C. 
(Fig. 4, lane C). These data are in agreement  with the con- 
cept (substantiated by the functional analysis of >300 clones) 
that, in donor E.C.,  only the inhibitory form (58 kD) of 
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Figure  3.  Comparative  analysis of [Ca + + ]i increase in NK clones expressing either inhibitory or activatory EB6 receptors. NK clones (derived from 
donor R,P.) characterized by either an inhibitory (done P7.6) or activatory EB6 receptor (clones P10.10 and P5.8) were analyzed for [Ca + + ]i mobiliza- 
tion after stimulation with anti-CD16 (A-C)  or anti-EB6  (D-F)  mAbs followed by isotype-specific  GAM.  While the [Ca + + ]i increments  induced 
by anti-CD16 mAb occurred  also  in the absence  of GAM-mediated cross-linking,  the latter was needed  for  the anti-EB6  mAb-mediated [Ca + +]i 
increments. 
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NK cell  populations  or NK clones  derived  from two different  donors  were 
surface labeled with IzsI, lysed in 1% NP-40, immunoprecipitated  with 
Sepharose  CnBr-coupled  anti-EB6  mAbs, and analyzed  in 8% SDS-PAGE 
under reducing  conditions. Lanes  B and E, a polyclonai  NK cell popula- 
tion from  donor R.P.; lane C, a polyclonal  NK cell  population  from  donor 
E.C.; lane F, clone P7-6 from donor R.P. expressing  an inhibitory  EB6 
receptor;  lanes G and H, clones  P10-3 and P5-5, both expressing  an activa- 
tory EB6 receptor.  In lanes  A and D, the two polyclonal  NK cell  popula- 
tions (from  donor E.C. and R.P., respectively)  were  immunoprecipitated 
with Sepharose  CnBr-coupled  JT3a mAb (anti-CD3) as a negative  control. 
the EB6 receptor is expressed. On the other hand, the pres- 
ence of  both 50- and 58-kD EB6 molecules in the polyclonal 
population derived from donor R.P. is likely to reflect the 
clonal heterogeneity of the functional responses (i.e., the pres- 
ence of NK cells expressing either the activatory or the in- 
hibitory form of EB6 receptor). To analyze whether the 58- 
kD band detected in the polyclonal population derived from 
donor R.P. indeed correlated with the inhibitory function, 
we analyzed the EB6 molecules immunoprecipitated from 
two clones isolated from donor R.P., which expressed an in- 
hibitory EB6 receptor (see also Fig. 1). Fig. 4 (lane F) shows 
one of these clones.  It is evident that the immunoprecipi- 
tated molecules displayed a molecular mass of '~,58 kD, thus 
indicating that, also in donor R.P., the expression of 58-kD 
EB6 molecules correlates with the expression of inhibitory 
EB6 receptors. 
Deglycosylation  of p58 and I>50 Molecules.  We next ana- 
lyzed whether the differences in molecular mass between the 
50- and the 58-kD molecules could be due to a differential 
glycosylation. In these experiments, clones displaying either 
activatory or inhibitory EB6 receptors were derived from two 
different donors (R.P. and G.T.). Similar to donor R.P., donor 
G.T.  was  characterized by GL183-/EB6 +  NK clones dis- 
playing  opposite  functional  responses  to  EB6-mediated 
triggering.  EB6 molecules were immunoprecipitated from 
GL183-/EB6  + clones expressing  either the 50- or the 58-kD 
form of receptor. The two immunoprecipitates were subjected 
to N-glycanase digestion  and analyzed by SDS-PAGE.  As 
shown in Fig.  5 a,  after deglycosylation, the 58-kD mole- 
cules displayed a 42-kD molecular mass, whereas the 50-kD 
molecules resulted in a 36-kD band. The low molecular mass 
bands that are detectable in the digested samples in some in- 
stances  are caused by background proteolytic activity of the 
N-glycanase enzyme. We also analyzed the 58- and the 50-kD 
molecules immunoprecipitated from the polydonal GL183-/ 
EB6 + population derived from donor R.P. In these experi- 
ments (Fig. 5 b), the anti-EB6 immunoprecipitates were treated 
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Figure 5.  Deglycosylation  of the EB6 molecules. (a) EB6 molecules 
immunoprecipitated  from surface-labeled  NK clones derived  from donor 
R.P. (lanes  A-D) or donor G.T. (lanes E-H) were subjected or not to 
N-glycanase  digestion.  Samples  were  analyzed  in an 11% SDS-PAGE  under 
reducing conditions.  Lanes  A and B (clone  P9.3) and lanes E and F (done 
Oo4.1) express  an activatory  EB6 receptor;  lanes C and D (clone  P8.1) and 
lanes G and H (clone  G4.9) express  an inhibitory  EB6 receptor. (b) EB6 
molecules immunoprecipitated  from a surface-labeled  polyclonal  NK cell 
population derived  from  donor R.P. Lanes  A-D, EB6 molecules treated 
with N-glycanase  (lane  B), neuraminidase (lane C), neuraminidase  plus 
O-glycanase (lane D). In lane A, undigested EB6 molecules are shown. 
Samples were run in a 11% SDS-PAGE  under reducing  conditions. Lanes 
E-H, the EB6 immunoprecipitate  was run in SDS-PAGE  and, after 4 h 
of exposure, the p58 and p50 bands were separately  excised  from the gel, 
eluted, digested or not with N-glycanase, and analyzed  in an 11% SDS- 
PAGE  under  reducing  conditions.  Lanes  E and F, P58 EB6 molecules;  lanes 
G and H, P50/EB6 molecules. 
with N-glycanase or with neuraminidase, followed or not 
by O-glycanase. In this case  as well,  after treatment with 
N-glycanase, the EB6 molecules displayed a 42- and 36-kD 
molecular mass.  The fact that the 42- and the 32-kD pro- 
teins were derived from the 58- and the 50-kD proteins, respec- 
tively, was confirmed in experiments in which the two EB6- 
reactive molecules were excised from the gel and separately 
digested with N-glycanase. Treatment with neuraminidase 
slightly decremented the mobility of the two proteins, thus 
indicating that both are sialated.  In addition, treatment with 
neuraminidase followed by O-glycanase had no further effects 
on mobility, indicating that no O-linked sugars are present. 
All together, these experiments indicated that the different 
molecular masses of the two anti-EB6-reactive molecules do 
not reflect a differential glycosylation of the same  surface 
protein. Comparative Analysis of p50 and p58 Molecules after Treat- 
ment with Proteolytic Enzymes.  On the basis of the above 
results,  it  was  important  to  establish  whether  the  two 
anti-EB6-reactive  molecules belonged to the same molecular 
family or to unrelated proteins. Thus, we further compared 
the p58 and the p50 molecules immunopredpitated  by anti- 
EB6 mAbs from 12SI-surface-hbeled  polydonal NK cells de- 
rived from donor R.P. Again, the two proteins were excised 
from the gel and digested separately with different enzymes, 
including VS-protease, chymotrypsin, and papain. As shown 
in Fig.  6 a, the pattern of digestion of the two molecules 
was, in most instances, similar; although some differences  could 
be detected after papain digestion (lanes C and D). To fur- 
ther substantiate these findings, the isohted p58 and the p50 
molecules were analyzed by two-dimensional peptide map- 
ping after treatment with pepsin. As shown in Fig. 6 b, aU 
the major peptides were shared by the two EB6 proteins, al- 
though at least one major peptide unique for each form could 
be detected. All together, these data indicate that the p58 
and the p50 molecules recognized by the EB6 mAb are rep- 
resentative  of strictly related  surface proteins. 
Figure 6.  Proteolytic digestion of P58 and P50/EB6  molecules. (a) P58- 
and P50/EB6-reactive  molecules immunoprecipitated from a polyclonal 
population derived from donor R.P. were separately excised from the gel. 
The two proteins were analyzed in a 15-20% gradient SDS-PAGE under 
reducing conditions, undigested (A, B) or digested with papain (C, D), 
VS-protease (E, F), or chymotrypsin (G, H). P58 molecules are shown 
in lanes A, C, E,  and G, and PS0 molecules  are shown in lanes B, D, 
F, and H. (b) Comparative analysis of the two-dimensional peptide maps 
of P58 (A) and PS0 (/3) molecules.  The two molecules were separately 
excised  as above, eluted, and cligested  with pepsin. Equal amounts of samples 
were spotted on a silica gel plate,  and peptides were separated by elec- 
trophoresis (vertical dimension) and chromatography (horizontal dimension). 
Arrows indicate peptides that appear to be specific for P58 and P50 mole- 
cules, respectively. 
Recognition of Cw4 Molecules by the pSO/EB6 Activatory 
Receptor.  Since p50 molecules reacted with anti-EB6 mAbs 
and displayed a high degree of structural homology  with the 
p58-inhibitory  EB6  receptors,  we  investigated  whether 
pS0/EB6 molecules also  specifically recognized Cw4 and 
related alleles. The data reported in Fig  1, which show a 
strong cytolytic activity against Cw4 + C1R cells, are com- 
patible with the occurrence of an interaction between EB6 
and Cw4 molecules leading to triggering of cytolytic activity. 
To directly assess this possibility,  we analyzed two groups 
of NK clones expressing the inhibitory or the activatory form 
of EB6 molecules, respectively. Their cytolytic activity against 
CIR cells was evaluated either in the absence or in the pres- 
ence of anti-EB6 mAb. As shown in Fig. 7, clones expressing 
the conventional  p58 EB6 receptor (A) did not kill CIR cells 
unless anti-EB6 mAb was added (13, 21). On the contrary, 
clones carrying the p50/EB6 molecules (B) were highly cyto- 
lyric against Cllk cells in the absence of anti-EB6 mAb. Upon 
addition of the mAb, 7 out of 12 clones were inhibited to 
a  significant  extent  (i.e.,  >50%  inhibition  of cytolysis), 
whereas the remaining 5 were not, or were only marginally, 
inhibited. In both instances, clones were derived from three 
different donors. These data are compatible with the concept 
that, in a fraction of the p50/EB6 + clones, the interaction 
between EB6 and Cw4 molecules represents a major trig- 
gering stimulus for inducing cytolytic activity.  Additional 
still undefined activatory receptor(s) are likely to play a major 
role in triggering the cytolytic activity of the remaining five 
clones  analyzed. 
More  conclusive evidence  that  the  p50/EB6  receptors 
specifically recognize Cw4 molecules was obtained in experi- 
ments in which NK clones were analyzed for cytolytic ac- 
tivity against untransfected or HLA-C-transfected LCL721.221 
target cells. Thus, as shown in Fig.  8,  four representative 
p50/EB6 + clones, selected on the basis of low cytolytic ac- 
tivity against the untransfected cell line, efficiently killed the 
Cw4 + but  not  the untransfected cells or  the Cw3 +  cell 
transfectants.  However,  two clones  expressing  an identical 
p50/EB6 + phenotype (RP32 and G69) but displaying the 
same magnitude of cytolytic activity against both transfected 
and untransfected ceils are shown. A likely explanation for 
the behavior of the latter two clones is the same as that pro- 
posed above for the five clones that were not inhibited by 
anti-EB6 nabs (see Fig 7); i.e., that they may express addi- 
tional triggering receptors. 
Cross-talh between  p58 or p50 Molecules and Other Receptors 
for HLA Class I Molecules.  Previous studies indicated that 
the (inhibitory) p58/EB6 receptor can (infrequently) be coex- 
pressed with inhibitory CD94 molecules, which function as 
putative receptors for some HLA-B alleles, including B7, B8, 
and B14 (14). However, in most clones, the p58/EB6 receptor 
is coexpressed with a noninhibitory form of CD94 molecule 
(14). On the contrary, the p50/EB6 + clones derived from 
donor R. P. and analyzed in the present study displayed an 
inhibitory CD94 receptor.  In addition, in this donor, clones 
carrying inhibitory (p58) EB6 molecules coexpressed nonin- 
hibitory CD94 molecules. 
Recent studies indicated that some NK clones can be acti- 
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Figure  7.  Effect  of anti-EB6 
mAb on the cytolytic  activity  of 
NK clones expressing  inhibitory 
or activatory  EB6 receptors. The 
cytolytic  activity  of 12 represen- 
tative EB6+ clones  expressing  the 
inhibitory  p58/EB6 receptor  (A) 
was compared  with that of 12 rep- 
resentative clones expressing the 
activatory  p50/EB6 receptor  (B). 
In both cases, clones  were  derived 
from three different  donors. The 
cytolytic activity against C1R 
(Cw4  +) cells was determined in 
a slCr release assay either in the 
presence or in the absence of 1 
/~g/ml of anti-EB6 mAb. The 
dotted lines  represent  3 SD above 
the mean spontaneous stCr re- 
lease. Each point represents the 
control  versus  the "inhibited"  cy- 
totoxicity  values  of a single  done. 
In B, clones resistant to the anti- 
EB6  mAb-mediated inhibition 
would thus fall close to the 45  ~ 
line. 
rated by anti-CD94 mAbs when analyzed in a redirected 
killing assay (22). Clones coexpressing EB6 and CD94 mol- 
ecules were further analyzed to assess the effect of the simul- 
taneous cell signaling via both receptors. To this end, clones 
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Figure  8.  Specific  recognition  of Cw4 molecules  by clones expressing 
the pS0/EB6 receptors.  In these  experiments,  target  cells  were  represented 
by the HLA class I-negative  LCL721.221 human cell line either untrans- 
fected I-l or transfected  with Cw4 ￿9  or Cw3 ~  aUdes. Six representative 
clones expressing  the activatory  pS0/EB6  receptor  and two control  clones 
(AM1 displaying the GL183-/EB6- phenotype  and EC246 expressing 
the p58/EB6  inhibitory  receptor)  have  been  used as effector  cells. The E/T 
ratio used in this experiment was 1:1. 
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were analyzed for their ability to lyse P815 target cells either 
in the absence or in the presence of anti-EB6 or anti-CD94 
mAb,  alone or used in combination. As shown in Fig.  9, 
target cell lysis by GL183-/EB6 +/CD94  l~  clones (14) iso- 
lated from donor E.C.  (A) was strongly triggered by anti- 
CD94 mAbs, while it was inhibited by anti-EB6 mAbs. The 
simultaneous addition of both mAbs resulted in a strong in- 
hibition of target cell lysis. In control experiments, in which 
anti-CD94  was  added  together with  an  anti-CD56  mAb 
(matched for isotype, IgG1), lysis of P815  target cells was 
comparable to that elicited by anti-CD94 mAb  alone. 
A  similar  analysis  was  performed  in  GL183-/EB6+/ 
CD94~s  ht clones from donor R.P. In most of these clones, 
anti-EB6 mAb was strongly stimulatory, whereas anti-CD94 
mAb was inhibitory (Fig. 9 B). When the two mAbs were 
mixed together, a strong inhibition of target cell lysis also 
occurred. Thus, activation via EB6 molecules was inhibited 
by anti-CD94 mAb. Another done (P7-6) derived from donor 
R.P.  but  characterized  by  the  GL183-/EB6+/CD94  l~ 
phenotype was stimulated by anti-CD94 mAb and inhibited 
by anti-EB6 mAbs. The simultaneous addition of the two 
mAbs resulted in sharp inhibition of cytolytic activity against 
P815  ceils in this done as well. 
In line with these resuhs, NK clones derived from donor 
R.P. and characterized by activatory p50/EB6 receptors and 
inhibitory CD94 receptors did not lyse target ceils coexpressing 
Cw4 and B7 alleles (14).  Thus, 9 out of 10 representative 
GL183-/EB6+/CD94bns  ht  clones  from  donor  R.P.  effi- 
ciently lysed C1R cells  (Cw4 §  but not C1R  cells  trans- 
fected with the HLA-B7 allele (not shown). Some of these 
clones were unable to lyse C1R cells transfected with the HLA- 
B27  allele.  Moreover, two out  of three dones that  killed 
C1R/B7 cells did not lyse C1R/B27 (14).  In this context, 
we provided evidence that the putative NK receptors for HLA- P9-3  P7-6 
75-- 
50-- 
Z$-- 
0 
ET162  EC456 
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EC237  ical analysis of anti-EB6 mAb-reactive molecules revealed that 
the activatory EB6 receptor displayed a molecular mass of 
50 kD, thus differing from the conventional inhibitory form 
(58 kD). As for the induction of EB6-mediated inhibition 
of NK cytotoxidty (11, 12), cross-linking of  p50/EB6 receptors 
was required toinduce NK cell activation. Finally, cross-linking 
of the activatory but not of the inhibitory form of EB6 mol- 
ecules induced [Ca + +]i increases. 
The inhibitory form (p58) of EB6 receptor (12) has been 
detected in all donors analyzed so far. On the other hand, 
the p50-activatory receptor could be detected only in some 
individuals.  Thus, the majority of donors (6 out of 10 donors 
tested) expressed exclusively the inhibitory form (e.g., donor 
E.C.), while others (4 donors out of 10) e~pressed both forms 
(e.g., donor R.P.). Moreover, in the latter donors, activatory 
and inhibitory EB6 receptors were simultaneously present and 
were expressed by different NK clones. Therefore, it has been 
possible to compare NK clones expressing either activatory 
or inhibitory receptors isolated from the same donor. 
Since differences in molecular mass could reflect differences 
in glycosylation of the same surface protein, purified p50 and 
p58 molecules were treated with neuraminidase, O-glycanase, 
and N-glycanase. After this enzymatic treatment, the pro- 
tein backbones of the two molecules displayed a different mo- 
lecular mass.  Although both p58  and p50 molecules were 
recognized by the same anti-EB6 mAb, it was possible  that 
they belonged to unrelated molecular species. To clarify this 
point, purified p50 and p58 EB6 molecules were treated with 
various proteolytic enzymes and analyzed in one- and two- 
dimensional peptide mapping. These experiments indicated 
that p50 and p58 molecules belong to the same molecular 
family, since most of the major peptides migrated in iden- 
tical positions and only one peptide was different. 
Our present results may offer a possible interpretation of 
data reported in our original paper describing the GL183 mol- 
ecules (11). In this paper we showed that, from some NK 
clones isolated from donor G.T., two molecules could be im- 
munoprecipitated by the GL183 mAb. Thus, while most clones 
expressed  a  58-kD  band  only,  the  58-kD  molecule was 
coprecipitated in some clones with a second molecule dis- 
playing a slightly lower molecular mass.  Since,  in further 
studies of GL183+/EB6 +  clones, we showed that  GL183 
and EB6 molecules could be coprecipitated by using either 
anti-EB6 or anti-GL183 mAb (21), it is possible that the lower 
band in the anti-GL183 immunoprecipitates corresponded to 
the presently defined p50/EB6 molecule. Indeed, recent anal- 
ysis of GL183+/EB6 + dories derived from the same donor 
(G.T.) revealed the existence of clones that coexpressed an in- 
hibitory GL183 and an activatory EB6 molecule (Moretta, 
A., unpublished data). 
The question of how to explain the molecular and func- 
tional differences between the two forms of EB6 receptors 
arises.  Analysis of the Ca ++  mobilization  in response to 
mAb-induced EB6 cross-linking clearly indicated that only 
the activatory EB6 receptors transduced signals resulting in 
[Ca++]i increments. No [Ca++]i increments could be de- 
tected in 20 clones expressing the inhibitory EB6 receptor, 
after cross-linking of the EB6 molecules. 
Existence of p58 and p50 Receptors for HLA-C Molecules in Human NK Cells 
B  plo-3 
loo 
7s 
u.~  so 
c~ 
A 
Figur, 9.  The cross-talk  between  EB6 and CD94 molecules  regulates 
the cytolytic  responses of GL183-/EB6  § clones. Three representative 
GL183-/EB6 + clones derived from donor E.C. (,4) or donor K.P. (B) 
were analyzed  for cytolytic  activity against P815 target cells either in the 
absence [~ or in the presence  of various mAbs. (A) Anti-CD16 II anti- 
EB6 ~, anti-CD94 [], anti-CD16 + anti-EB6 D, anti-CD94 + anti- 
EB6 ~. (B) Anti-CD16 am  anti-EB6 ~, anti-CD94 i~, anti-CD16 + 
anti-CD94 m, anti-EB6 + anti-CD94 ~. Data are expressed  as the per- 
centage of specific slCr rdease at an E/T ratio of 5:1. 
B7 and HLA-B27, although distinct, can be coexpressed by 
the same NK clone (14). These data suggest that clones ex- 
pressing activatory pS0/EB6 receptors are negatively controlled 
by one or more inhibitory receptors specific for other HLA 
class I alleles. 
Discussion 
In this study, we provide evidence that EB6 molecules, 
known to function as inhibitory NK receptors specific for 
a group of HLA-C alleles (13, 21), may also function as ac- 
tivatory receptors mediating NK cell triggering. Biochem- 
882 These data suggest  that pS0 and p58 molecules may be 
coupled to different pathways of signal transduction. This 
may reflect differences in the cytoplasmic tails of pS0 and p58 
molecules, possibly related to divergent amino acid sequences 
within this portion of the molecules. Precise information on 
this matter will be soon available, since molecular cloning 
of different cDNAs that encode for surface proteins reacting 
with anti-p58 mAbs (in cell transfectants) has recently been 
performed (23a). 
It is undear why some individuals express only the inhibi- 
tory form of EB6 molecules while others express both the 
activatory and the inhibitory forms. One could speculate that, 
in some donors, the NK receptor repertoire may be shaped 
in the course of certain pathological conditions. Another pos- 
sible explanation is that the MHC haplotype itself, thought 
to be responsible for the shaping of the NK cell repertoire, 
may operate not only by selecting NK receptors specific for 
self HLA class I alleles, but also by influencing the functional 
type (activatory or inhibitory) of receptor selected. Interest- 
ingly, in most instances, clones expressing a p58-inhibitory 
receptor coexpressed activatory CD94 or NKBl-homologous 
z27/p70 receptors (23b) and vice versa. Therefore, a balancing 
effect appears  to  exist  between activatory  and inhibitory 
receptors  at the clonal level. 
The finding that EB6 + (p50) clones displayed a strong 
cytolytic activity against C1R (Cw4 +) cells suggested that 
the activatory EB6 receptors may play a relevant role in NK 
cell triggering as a consequence of the recognition of Cw4 
molecules. In previous studies, a correlation between expres- 
sion of given HLA-C alleles on target cells and expression 
of the corresponding receptor on NK clones had been sug- 
gested by the analysis of the segregation of the antigen rec- 
ognized in representative families (9). However, this approach 
was not informative for NK clones expressing the activatory 
p50/EB6 molecules, because of the coexpression of other in- 
hibitory  or  stimulatory  receptors.  Therefore,  pS0/EB6 + 
clones were analyzed against a panel of target cells from HLA- 
homozygous donors in an attempt to lower the number of 
potentially recognized HLA dass I alleles. A fraction of these 
clones lysed target cells expressing Cw4 or related alleles but 
not those expressing Cw3 and related alleles. However, an- 
other fraction of pS0/EB6 + clones could lyse only some of 
the HLA-homozygous target cells expressing Cw4 or related 
alleles. Again, a likely explanation for this heterogeneity could 
be the coexpression, in these dones, of inhibitory receptors 
for either HLA-B or HLA-A alleles expressed on target cells. 
We next showed that anti-EB6 mAbs strongly inhibited killing 
of C1R cells by a fraction of EB6 + (p50) clones (Fig. 7). 
These data suggest that the interaction between the EB6 NK 
receptors and Cw4 molecules expressed on target cells plays 
an important role in triggering the cytolytic activity of these 
clones. Another fraction of clones was not inhibited or was 
only marginally inhibited by anti-EB6 mAbs. This implies 
that different activatory receptor(s) (nompecific for MHC dass 
I molecules) are likely to be responsible for triggering the 
cytolytic function of these clones. This interpretation was 
further supported by experiments in which pS0/EB6 + NK 
dones  were  analyzed  against  the  HLA  dass  I-negative 
LCL721.221 cell line, either untransfected or transfected with 
Cw4 or Cw3 alldes. In these experiments, increments of cyto- 
lyric activity against Cw4 transfectants could be detected only 
in a fraction of the dones analyzed. 
A possible involvement of MHC molecules in NK cell trig- 
gering has been previously suggested by experiments  on al- 
loreactive NK cells isolated from certain strains of rats (24). 
Indeed, it has been shown that the genetic trait "suscepti- 
bility to lysis" cosegregated with certain MHC class I haplo- 
types in a dominant way. These data are compatible with 
the existence of activatory receptors of MHC class I in rat 
NK cells. 
Taken together, our present results suggest that the cyto- 
lyric function of NK cells may be regulated by the balance 
between positive and negative signals delivered by the inter- 
action between NK receptors and their specific  MHC ligands. 
Thus, MHC molecules would not only be responsible for 
the protection of potential target cells but would also be in- 
volved in NK cell triggering. Based on our data, it appears 
that the positive signals delivered by MHC molecules to NK 
cells can be revealed only in the absence of effective inhibi- 
tory interactions. This event would occur in pathological con- 
ditions characterized by down-regulation or masking of the 
protective MHC allele(s), such as in tumor transformation 
or viral infections.  Whether the MHC-induced triggering 
of the NK-mediated cytotoxicity can be regarded as a major 
pathway of NK cell activation remains to be determined. In 
this context, it is important to note that HLA-negative cells 
are highly susceptible to the NK cell-mediated lysis. Obvi- 
ously, in this case, no NK cell triggering can be induced by 
activatory receptor-MHC interactions,  and the existence of 
activatory receptors specific for ligands that are different from 
MHC molecules must, be postulated. Our present data confirm 
the relevance of the  missing self" hypothesis as the major 
event in rendering autologous target cells susceptible to NK 
cell-mediated cytolysis (1-5).  However, they show that the 
simultaneous expression on autologous cells of self class I al- 
Ides that interact with activatory NK receptors may be respon- 
sible for the induction or at least for the potentiation of the 
cytolytic activity of NK cells. 
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